Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Present at the 2021 Jefferies London Healthcare Conference
November 10, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Nov. 10, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that Evan Loh, chief executive officer, will present at the 2021 Jefferies London Healthcare...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces Total Revenue of $24.4 Million in the Third Quarter 2021
November 08, 2021 16:05 ET | Paratek Pharmaceuticals
-- NUZYRA® (omadacycline) Generated Net U.S. Sales of $19.4 Million from the Core Commercial Business alone, a 30% Increase over Prior Quarter -- BARDA Contract Expanded to Include sNDA Anthrax...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Report Third Quarter 2021 Financial Results on Nov. 8, 2021
November 01, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the company will host a conference call and live audio webcast on Monday, Nov. 8, 2021 at...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
November 01, 2021 16:04 ET | Paratek Pharmaceuticals
BOSTON, Nov. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces Enrollment of First Patient in Phase 2b Study Evaluating NUZYRA® (omadacycline) for Nontuberculous Mycobacterial (NTM) Pulmonary Disease Caused by Mycobacterium abscessus Complex (MABc)
October 18, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Oct. 18, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) today announced that the first patient has been enrolled in the company’s Phase 2b study evaluating the safety...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
October 01, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Oct. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Announces Additional Funding Under the BARDA Contract to Advance the Development of NUZYRA® (omadacycline) for Post-Exposure Prophylaxis (PEP) and Treatment of Pulmonary Anthrax
September 27, 2021 16:05 ET | Paratek Pharmaceuticals
-- Additional ~$19M Funding for Expanded Anthrax PEP Development Program -- BARDA Contract Now Valued at Up to ~$304M -- Development Milestones Specified for Future Procurements ...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals Presenting New Data for NUZYRA® (omadacycline) at IDWeek 2021
September 23, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Sept. 23, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK) announced today that data from the NUZYRA® (omadacycline) clinical and microbiology programs are being...
Paratek Pharmaceuticals Logo
Paratek Pharmaceuticals to Present at H.C. Wainwright 23rd Annual Global Investment Conference
September 09, 2021 08:30 ET | Paratek Pharmaceuticals
BOSTON, Sept. 09, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...
Paratek Pharmaceuticals Logo
Paratek Announces Inducement Grants under NASDAQ Listing Rule 5635(c)(4)
September 01, 2021 16:05 ET | Paratek Pharmaceuticals
BOSTON, Sept. 01, 2021 (GLOBE NEWSWIRE) -- Paratek Pharmaceuticals, Inc. (Nasdaq: PRTK), a commercial-stage biopharmaceutical company focused on the development and commercialization of novel...